Keep Your Teethby KYT Dental Services
Denosumab (Prolia) · § 00/Jaw bone problems (MRONJ)

Denosumab and medication-related osteonecrosis of the jaw (MRONJ)

What MRONJ risk looks like on denosumab, how it differs from bisphosphonate-related risk, and how dose timing changes dental planning.

Bone and surgeryPhysician coordination

Never start, stop, or change a medication based on what you read here. Bring questions to your dentist, physician, pharmacist, or prescribing clinician.

Quick answer

Denosumab (Prolia, Xgeva) carries an MRONJ risk similar to bisphosphonates, but managed differently because the drug effect reverses within months of stopping. The osteoporosis dose (Prolia, 60 mg every 6 months) has lower MRONJ rates than the cancer dose (Xgeva, given more frequently). Invasive dental work is often timed in the months before the next scheduled injection, when bone turnover has partially recovered. The right move is not to avoid dental care; it is to coordinate it.

The mechanism

How denosumab MRONJ differs from bisphosphonate MRONJ

Denosumab is a monoclonal antibody that blocks RANK ligand, the signal that activates the osteoclasts which break down bone. Without that signal, bone breakdown slows dramatically, which is what makes denosumab effective for osteoporosis and bone protection during cancer treatment. The downside is that the same suppression of bone turnover slows healing at sites of surgical trauma to the jaw, raising MRONJ risk.

The big difference from bisphosphonates is the duration of effect. Bisphosphonates bind tightly to bone and continue working for years after stopping. Denosumab effects fade within months of the last injection. This makes timing of invasive dental procedures more flexible: in patients on the osteoporosis dose (Prolia every 6 months), there is a recognizable window of partial recovery in the weeks before the next dose where dental surgery is generally safer.

The cancer dose (Xgeva, typically every 4 weeks for bone metastases or multiple myeloma) is given more frequently and at higher cumulative doses than Prolia. MRONJ rates with Xgeva are substantially higher than with Prolia. Patients on Xgeva need much more careful coordination between their oncology team and their dentist before any invasive dental work.

Practical steps

What to do if you are on denosumab and need dental work

Tell your dentist at scheduling that you are on denosumab and which form (Prolia for osteoporosis or Xgeva for cancer).
Tell us when your last injection was and when the next is scheduled. The timing changes how we plan.
Address any infected or hopeless teeth promptly. A tooth abscess is harder on the jaw than a planned extraction.
Do not skip or delay denosumab on your own. The decision is made with your prescribing physician, and timing dental work around the dose schedule is usually a better approach than stopping the medication.
If you are about to start denosumab, have any planned dental work done first if possible. Pre-treatment optimization is one of the highest-leverage protections.
Maintain meticulous oral hygiene. The local bacterial load matters for MRONJ risk.

Signs to watch for

When to call your dentist

  • An exposed area of bone in the mouth, even if it is not painful.
  • A tooth socket that is not healing weeks after an extraction.
  • Persistent jaw pain in the area of a recent procedure.
  • A non-healing sore on the gums that has been there more than two weeks.
  • Numbness or tingling in the jaw, lip, or chin (this can be a sign of bone involvement).

Common questions

What patients ask about Denosumab (Prolia) and jaw bone problems (mronj)

KYT Framework

KYT Framework connection

Four questions that shape how Denosumab (Prolia) and jaw bone problems (mronj) factor into dental planning.

Structure

Does jaw bone problems (mronj) change bone, gum tissue, saliva, enamel, or healing support?

Force

Will chewing, grinding, or bite pressure create added risk for vulnerable teeth or healing tissue?

Timing

Is jaw bone problems (mronj) something to prevent now, monitor, or evaluate soon?

Stability

What plan gives the mouth the best chance to stay stable?

Taking Denosumab (Prolia) and noticing jaw bone problems (mronj) changes?

Bring your medication list. KYT can evaluate cavity risk, gum health, and treatment timing in person.

Reviewed by Dr. Isaac Sun, DDS · KYT Dental Services · Fountain Valley, CA · Last reviewed: June 2026

This page is general patient education. It does not replace advice from your prescribing clinician, physician, pharmacist, or dentist. Medication information may change; verify with your clinical team.